High-molar contrast agents for CNS application

Imaging Decisions MRI

Volumn 11, Issue 4, 2008, Pages 26-32

  Engelhorn, T ^a   Doerfler, A ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Contrast media; Dose; MRA; MRI; PWI

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIDOL; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;

ANAPHYLAXIS; ARTICLE; BRAIN METASTASIS; BRAIN PERFUSION; CONTRAST ENHANCEMENT; DRUG CHOICE; DRUG EXCRETION; DRUG PROTEIN BINDING; GLIOMA; HEADACHE; HEAT SENSATION; HUMAN; IMAGE QUALITY; MAGNETIC RESONANCE ANGIOGRAPHY; MULTIPLE SCLEROSIS; NAUSEA; NEPHROGENIC FIBROSING DERMOPATHY; NEPHROGENIC SYSTEMIC FIBROSIS; NEPHROGENIC SYSTEMIC SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OSMOLALITY; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; URTICARIA; VOMITING;

EID: 38349154201     PISSN: 14333317     EISSN: 16170830     Source Type: Journal    
DOI: 10.1111/j.1617-0830.2007.00107.x     Document Type: Article

References (33)

1. Reiser M., Semmler W. Magnetresonanztomographie. Auflage 2002 Kap. 7 Kontrastmittel : 111 132.
2. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006 21 : 1104 1108.
3. Pintaske J, Martirosian P, Graf H et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3T. Invest Radiol 2006 41 : 213 221.
4. Benner T, Reimer P, Erb G et al. Cerebral MR perfusion imaging: first clinical application of a 1 M gadolinium chelate (Gadovist 1.0) in a double-blinded randomized dose-finding study. J Magn Reson Imaging 2000 12 : 371 380.
5. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Investigative. Radiology 2005 40 : 715 724.
6. Rowley HA, Roberts TP. Clinical perspectives in perfusion: neuroradiologic applications. Top Magn Reson Imaging 2004 48 : 53 58.
7. Tombach B, Benner T, Reimer P et al. Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 versus 1.0 mol/L gadobutrol. Radiology 2003 226 : 880 888.
8. Chu WC, Lam WW, Metreweli C. Incidence of adverse events after i.v. injection of MR contrast agents in a Chinese population. A comparison between gadopentetate and gadodiamide. Acta Radiol 2000 41 : 662 666.
9. Li A, Wong CS, Wong MK, Lee CM, Au-Yeung MC. Acute adverse reactions to resonance contrast media - gadolinium chelates. Br J Radiol 2004 79 : 368 371.
10. Marckmann P, Skov L, Rossen K et al. Nephrogenic systemic fibrosis: suspected ethiological role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006 17 : 2359 2362.
11. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk CA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Am J Roentgenol 2007 188 : 586 592.
12. Idée JM, Port M, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006 20 : 563 576.
13. Schneider G, Kirchin MA, Pirovano G et al. Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: effect of dose on lesion detection and delineation. J Magn Reson Imaging 2001 14 : 525 539.
14. Ba-Ssalamah A, Nöbauer-Huhmann IM, Pinker K et al. Effect of contrast dose and field strength in the magnetic resonance detection of brain metastases. Invest Radiol 2003 38 : 415 422.
15. Vogl TJ, Friebe CE, Balzer T et al. Diagnosis of cerebral metastasis with standard does gadobutrol vs. a high dose protocol. Intraindividual evaluation of a phase II high dose study. Radiologe 1995 35 : 508 516.
16. Lemke AJ, Sander B, Balzer T, Geens V, Hosten N, Felix R. Safety and use of gadobutrol in patients with brain tumors (phase III trial). Rofo 1997 167 : 591 598.
17. Erickson BJ, Campeau NG, Schreiner SA, Buckner JC, O'Neil BP, O'Fallon JR. Triple-dose contrast/magnetization transfer suppressed imaging of "non-enhancing" brain gliomas. J Neurooncol 2002 60 : 25 29.
18. Runge VM, Parker JR, Donovan M. Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelat with enhanced relaxivity, in malignant lesions of the brain. Invest Radiol 2002 37 : 269 280.
19. Engh JA, Flickinger JC, Niranjan A, Amin DV, Kondziolka DS, Lunsford LD. Optimizing intracranial metastasis detection for stereotactic radiosurgery. Stereotact Funct Neurosurg 2007 85 : 162 168.
20. Silver NC, Good CD, Barker GJ et al. Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain 1997 120 : 1149 1161.
21. Uysal E, Erturk SM, Yildirim H, Seleker F, Basak M. Sensitivity and delayed gadolinium-enhanced MRI after injection of 0.5 M and 1.0 M gadolinium chelates for detecting multiple sclerosis lesions. Am J Roentgenol 2007 188 : 697 702.
22. Rashid W, Davies GR, Chard DT et al. Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study. Mult Scler 2007 13 : 178 185.
23. Stecco A, Migazzo E, Saponaro A et al. Gadolinium dose optimisation in patients with multiple sclerosis: intra- and inter-individual comparisons. Eur J Radiol 2006 57 : 37 42.
24. Marchal G, Michiels J, Bosmans H, Van Hecke P. Contrast-enhanced MRA of the brain. J Comput Assist Tomogr 1991 16 : 25 29.
25. Tombach B, Heindel W. Value of 1.0 M gadolinium chelates: review of preclinical and clinical data on gadobutrol. Eur Radiol 2002 12 : 1550 1556.
26. Essig M, Lodemann KP, Le-Huu M, Bruening R, Kirchin M, Reith W. Intraindividual comparison of gedobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5T. Invest Radiol 2006 41 : 256 263.
27. Unterweger M, Froehlich JM, Kubik-Huch RA et al. Dose optimization of contrast-enhanced carotid MR angiography. Eur Radiol 2005 15 : 1797 1805.
28. Jourdan C, Heverhagen JT, Knopp MV. Dose comparison of single- vs. double dose in contrast-enhanced magnetic resonance angiography of the carotid arteries: intraindividual cross-over blinded trial using Gd-DTPA. J Magn Reson Imaging 2007 25 : 557 563.
29. Essig M, Nikolaous K, Meaney JF. Magnetic resonance angiography of the head and neck vessels. Eur Radiol 2007 17 (Suppl. 2 B30 B37.
30. Grandin CB, Duprez TP, Smith AM et al. Which MR-derived perfusion parameters are the best predictors of infarct growth in hyperacute stroke? Comparative study between relative and quantitative measurements Radiology 2002 223 : 361 370.
31. Martel AL, Allder SJ, Delay GS, Morgan PS, Moody AA. Perfusion MRI of infarcted and noninfarcted brain tissue in stroke: a comparison of conventional hemodynamic imaging and factor analysis of dynamic studies. Invest Radiol 2001 36 : 378 385.
32. Fuss M, Wenz F, Scholdei R et al. Radiation-induced regional cerebral blood volume (rCBV) changes in normal brain and low-grade astrocytomas: quantification and time and dose-dependent occurrence. Int J Radiat Oncol Biol Phys 2000 48 : 53 58.
33. Rempp KA, Brix G, Wenz F, Becker CR, Gückel F, Lorenz WJ. Quantification of regional cerebral blood flow and volume with dynamic susceptibility contrast-enhanced MR imaging. Radiology 1994 193 : 637 641.